InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China
Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity